AcuCort

AcuCort is an innovative, publicly traded Swedish pharmaceutical company with a mission to develop and commercialize 'smart drugs' based on existing, well-documented substances. Its core achievement is the approval and ongoing commercialization of Zeqmelit®, a proprietary oral film for acute conditions, now marketed in the Nordics with further registrations pending. The company's strategy is built on a capital-efficient, de-risked model that leverages a robust oral film technology platform to create patient-friendly treatments, which are then brought to market through regional and global licensing partners. This approach aims to deliver significant clinical and patient benefits while optimizing value creation for a company of its size.

Proprietary oral film drug delivery platform designed for rapid dissolution in the mouth without water, enabling quick mucosal absorption for fast onset of action and improved patient compliance.

Competes against generic dexamethasone formulations (tablets, liquids) on convenience and speed, and against other oral film technology companies on specific molecule expertise and first-mover approval. Positions as a complementary therapy in anaphylaxis management rather than a direct competitor to epinephrine.